The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Agarwal, Jasmin R ^a   Griesinger, Frank ^b   Stühmer, Walter ^a   Pardo, Luis A ^a  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; POTASSIUM CHANNEL HERG; RNA; SMALL INTERFERING RNA; ERG1 POTASSIUM CHANNEL;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; DNA SYNTHESIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LEUKEMIA RELAPSE; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; STEM CELL TRANSPLANTATION; UPREGULATION; ADOLESCENT; AGING; CHILD; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; INFANT; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PRESCHOOL CHILD; SURVIVAL; TREATMENT OUTCOME; TUMOR CELL LINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77949541790     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-18     Document Type: Article

References (38)

1. Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 2005, 11:1416-1424. 10.1158/1078-0432.CCR-04-1552, 15746041.
2. Muñoz L, Nomdedeu JF, Villamor N, Guardia R, Colomer D, Ribera JM, Torres JP, Berlanga JJ, Fernández C, Llorente A, et al. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells. Leukemia 2003, 17:76-82. 10.1038/sj.leu.2402708, 12529663.
3. Zwaan CM, Meshinchi S, Radich JP, Veerman AJ, Huismans DR, Munske L, Podleschny M, Hahlen K, Pieters R, Zimmermann M, et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood 2003, 102:2387-2394. 10.1182/blood-2002-12-3627, 12816873.
4. Ostendorf P, Seeber S. Hämatologie/Onkologie 1997, Munich: Urban & Fischer Verlag.
5. Stühmer W, Alves F, Hartung F, Zientkowska M, Pardo LA. Potassium channels as tumour markers. FEBS Lett 2006, 580:2850-2852. 10.1016/j.febslet.2006.03.062, 16783874.
6. Shieh CC, Coghlan M, Sullivan JP, Gopalakrishnan M. Potassium channels: Molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev 2000, 52:557-593.
7. Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov 2009, 8:982-1001. 10.1038/nrd2983, 19949402.
8. Camacho J, Sánchez A, Stühmer W, Pardo LA. Cytoskeletal interactions determine the electrophysiological properties of human EAG potassium channels. Pflugers Arch 2000, 441:167-174. 10.1007/s004240000420, 11211100.
9. Gómez-Varela D, Zwick-Wallasch E, Knötgen H, Sánchez A, Hettmann T, Ossipov D, Weseloh R, Contreras-Jurado C, Rothe M, Stühmer W, Pardo LA. Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity. Cancer Res 2007, 67:7343-7349. 10.1158/0008-5472.CAN-07-0107, 17671204.
10. Hemmerlein B, Weseloh RM, Mello de Queiroz F, Knötgen H, Sánchez A, Rubio ME, Martin S, Schliephacke T, Jenke M, Radzun HJ, et al. Overexpression of Eag1 potassium channels in clinical tumour specimens. Mol Cancer 2006, 5:41. 10.1186/1476-4598-5-41, 1621079, 17022810.
11. Mello de Queiroz F, Suárez-Kurtz G, Stühmer W, Pardo LA. Ether à go-go potassium channel expression in soft tissue sarcoma patients. Mol Cancer 2006, 5:42. 10.1186/1476-4598-5-42, 1618397, 17022811.
12. Pardo LA, del Camino D, Sánchez A, Alves F, Brüggemann A, Beckh S, Stühmer W. Oncogenic potential of EAG K+ channels. EMBO J 1999, 18:5540-5547. 10.1093/emboj/18.20.5540, 1171622, 10523298.
13. Pardo LA, Stühmer W. Eag1: an emerging oncological target. Cancer Res 2008, 68:1611-1613. 10.1158/0008-5472.CAN-07-5710, 18339837.
14. Martin S, Lino de Oliveira C, Mello de Queiroz F, Pardo LA, Stühmer W, Del Bel E. Eag1 potassium channel immunohistochemistry in the CNS of adult rat and selected regions of human brain. Neuroscience 2008, 155:833-844. 10.1016/j.neuroscience.2008.05.019, 18650019.
15. Bijlenga P, Occhiodoro T, Liu JH, Bader CR, Bernheim L, Fischer- Lougheed J. An ether-a-go-go K+ current, ih-eag, contributes to the hyperpolarization of human fusion-competent myoblasts. J Physiol 1998, 512:317-323. 10.1111/j.1469-7793.1998.317be.x, 2231207, 9763622.
16. Pardo LA, Brüggemann A, Camacho J, Stühmer W. Cell cycle-related changes in the conducting properties of r-eag K+ channels. J Cell Biol 1998, 143:767-775. 10.1083/jcb.143.3.767, 2148139, 9813096.
17. Schönherr R, Lober K, Heinemann SH. Inhibition of human ether a go-go potassium channels by Ca2+/calmodulin. EMBO J 2000, 19:3263-3271. 10.1093/emboj/19.13.3263, 313935, 10880439.
18. Meyer R, Heinemann SH. Characterization of an eag-like potassium channel in human neuroblastoma cells. J Physiol 1998, 508:49-56. 2230852, 9490815.
19. Farias LMB, Bermúdez Ocaña D, Díaz L, Larrea F, Avila-Chávez E, Cadena A, Hinojosa LM, Lara G, Villanueva LA, Vargas C, et al. Ether à go-go Potassium Channels as Human Cervical Cancer Markers. Cancer Res 2004, 64:6996-7001. 10.1158/0008-5472.CAN-04-1204, 15466192.
20. Downie BR, Sánchez A, Knötgen H, Contreras-Jurado C, Gymnopoulos M, Weber C, Stühmer W, Pardo LA. Eag1 expression interferes with hypoxia homeostasis and induces angiogenesis in tumors. J Biol Chem 2008, 283:36234-36240. 10.1074/jbc.M801830200, 2606018, 18927085.
21. Gavrilova-Ruch O, Schönherr K, Gessner G, Schönherr R, Klapperstuck T, Wohlrab W, Heinemann SH. Effects of imipramine on ion channels and proliferation of IGR1 melanoma cells. J Membr Biol 2002, 188:137-149. 10.1007/s00232-001-0181-3, 12172639.
22. Ouadid-Ahidouch H, Le Bourhis X, Roudbaraki M, Toillon RA, Delcourt P, Prevarskaya N. Changes in the K+ current-density of MCF-7 cells during progression through the cell cycle: Possible involvement of a h-ether.a-gogo K+ channel. Recept Channels 2001, 7:345-356.
23. Weber C, Mello de Queiroz F, Downie B, Sukow A, Stühmer W, Pardo LA. Silencing the activity and proliferative properties of the human Eag1 potassium channel by RNAi. J Biol Chem 2006, 281:13033-13037.
24. Smith GAM, Tsui HW, Newell EW, Jiang XP, Zhu XP, Tsui FWL, Schlichter LC. Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells. Journal of Biological Chemistry 2002, 277:18528-18534. 10.1074/jbc.M200592200, 11893742.
25. García-Ferreiro RE, Kerschensteiner D, Major F, Monje F, Stühmer W, Pardo LA. Mechanism of Block of hEag1 K+ Channels by Imipramine and Astemizole. J Gen Physiol 2004, 124:301-317. 10.1085/jgp.200409041, 2233905, 15365094.
26. Pillozzi S, Brizzi MF, Balzi M, Crociani O, Cherubini A, Guasti L, Bartolozzi B, Becchetti A, Wanke E, Bernabei PA, et al. HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors. Leukemia 2002, 16:1791-1798. 10.1038/sj.leu.2402572, 12200695.
27. Li H, Liu L, Guo L, Zhang J, Du W, Li X, Liu W, Chen X, Huang S. HERG K+ channel expression in CD34+/CD38-/CD123(high) cells and primary leukemia cells and analysis of its regulation in leukemia cells. International journal of hematology 2008, 87:387-392. 10.1007/s12185-008-0056-9, 18415658.
28. Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrozek K, Baldus CD, Vukosavljevic T, Liu CG, Ross ME, et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 2008, 111:5371-5379. 10.1182/blood-2007-11-124958, 2396728, 18378853.
29. Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S, Thomas X, Raffoux E, Lamandin C, Castaigne S, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002, 100:2717-2723. 10.1182/blood-2002-03-0990, 12351377.
30. Bianchi L, Wible B, Arcangeli A, Taglialatela M, Morra F, Castaldo P, Crociani O, Rosati B, Faravelli L, Olivotto M, Wanke E. HERG encodes a K+ current highly conserved in tumors of different histogenesis - a selective advantage for cancer cells?. Cancer Res 1998, 58:815-822.
31. Pillozzi S, Brizzi MF, Bernabei PA, Bartolozzi B, Caporale R, Basile V, Boddi V, Pegoraro L, Becchetti A, Arcangeli A. VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood 2007, 110:1238-1250. 10.1182/blood-2006-02-003772, 17420287.
32. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006, 440:463-469. 10.1038/nature04710, 16554806.
33. Feldman DL, Mogelesky TC. Use of Histopaque for isolating mononuclear cells from rabbit blood. Journal of immunological methods 1987, 102:243-249. 10.1016/0022-1759(87)90083-4, 3655375.
34. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucl Acids Res 2001, 29:e45. 10.1093/nar/29.9.e45, 55695, 11328886.
35. Ahmed N, Williams JF, Weidemann MJ. The human promyelocytic HL60 cell line: a model of myeloid cell differentiation using dimethylsulphoxide, phorbol ester and butyrate. Biochemistry international 1991, 23:591-602.
36. Meyer PA, Kleinschnitz C. Retinoic acid induced differentiation and commitment in HL-60 cells. Environmental health perspectives 1990, 88:179-182. 10.2307/3431071, 1568026, 2272312.
37. Trayner ID, Bustorff T, Etches AE, Mufti GJ, Foss Y, Farzaneh F. Changes in antigen expression on differentiating HL60 cells treated with dimethylsulphoxide, all-trans retinoic acid, alpha1,25-dihydroxyvitamin D3 or 12-O-tetradecanoyl phorbol-13-acetate. Leukemia research 1998, 22:537-547. 10.1016/S0145-2126(98)00041-1, 9678720.
38. Lawless JF. Statistical Models and Methods for Lifetime Data Book Description 2002, New York: Wiley Interscience, 2.